详情页 - 广东省中医院知识库

当前位置：首页 > 详情页

Serum nicotinamide phosphoribosyltransferase as a novel biomarker for non-traumatic osteonecrosis of the femoral head

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Department of Orthopedics, Linyi People's Hospital, Linyi, 276000, Shandong, China. [2]Guangzhou University of Chinese Medicine, Guangzhou, 513000, Guangdong, China. [3]Department of Laboratory Medicine, Qingdao Central Hospital, Second Affiliated Hospital of Qingdao University, Qingdao, 266042, Shandong, China

出处：

DOI：

关键词： Non-traumatic osteonecrosis of the femoral head Disease severity Nicotinamide phosphoribosyltransferase Biomarker

摘要：

The aim of this study was to investigate the potential role of serum nicotinamide phosphoribosyltransferase (NAMPT) in non-traumatic osteonecrosis of femoral head (NONFH).A total of 113 NONFH patients and 81 healthy individuals were included in this study. The NAMPT levels in serum were measured by a commercial enzyme-linked immunosorbent assay kit. Radiographic progression was determined using Association Research Circulation Osseous (ARCO) classification system. Clinical severity was assessed by Harris hip score (HHS) and visual analogue scale (VAS). Correlations between serum NAMPT and radiographic progression as well as clinical severity were evaluated statistically. Receiver operating characteristic (ROC) curves were performed to evaluate the diagnostic values of NAMPT in NONFH potential and disease severity.The serum NAMPT levels in NONFH patients were significantly lower than that in healthy controls. There were no significant differences among alcohol-induced group, steroids-induced group, and idiopathic group. NONFH patients with ARCO stage 4 had significant lower serum NAMPT levels in comparisons with ARCO stage 3 and 2, respectively. Lower serum NAMPT levels were also observed in bilateral NONFH cases compared with cases with unilateral NONFH. In addition, serum NAMPT was negatively correlated with ARCO stages and VAS scores, and positively correlated with HHS. ROC curve analysis indicated that serum NAMPT may serve as a novel biomarker for diagnosing early NONFH and for monitoring disease severity.Our results suggest that serum NAMPT may serve as a novel biomarker for NONFH potential and disease severity.© 2022. The Author(s).

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2021]版：

大类 | 3 区医学

小类 | 3 区骨科

最新[2025]版：

大类 | 3 区医学

小类 | 3 区骨科

第一作者：

第一作者机构： [1]Department of Orthopedics, Linyi People's Hospital, Linyi, 276000, Shandong, China.

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Attenuated serum adiponectin levels are associated with disease severity in patients with non-traumatic osteonecrosis of the femoral head. [2]Attenuated serum vasoactive intestinal peptide concentrations are correlated with disease severity of non-traumatic osteonecrosis of femoral head. [3]Reduced serum and local LncRNA MALAT1 expressions are linked with disease severity in patients with non-traumatic osteonecrosis of the femoral head. [4]Serum α-melanocyte-stimulating hormone may act as a protective biomarker for non-traumatic osteonecrosis of the femoral head. [5]Treatment of collapsed traumatic osteonecrosis of the femoral head in adolescents using non-vascularized bone grafting via the trapdoor procedure [6]A novel serological biomarker are associated with disease severity in patients with osteoarthritis [7]Multi-omics approach identifies PI3 as a biomarker for disease severity and hyper-keratinization in psoriasis [8]Cerebrospinal fluid MFG-E8 as a promising biomarker of amyotrophic lateral sclerosis [9]Comprehensive Profiling of Inflammatory Factors Revealed That Growth Differentiation Factor-15 Is an Indicator of Disease Severity in COVID-19 Patients [10]Elevated serum CCL4/MIP-1β levels in postmenopausal osteoporosis patients are linked with disease severity.